Attenuation of the second peak of bimodal recurrence of HBVrelated HCC after curative treatment in the antiviral era @JHepatology https://t.co/Lf8cnOUI6g 👉Antiviral therapies reduce overall recurrence in HBV-HCC after curative treatment @myESMO @EASLedu @ILCAnews

Satellite lesions vs intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling @HEP_Journal https://t.co/PLHIy9oUCQ 👉highly concordant mutational landscape of IM & SL 👉 poor long-term survival 🧐both should be categorized

What is the role of pre-op RT in esophagus/GEJ cancer post ESOPEC & now MATTERHORN? I think we all agree pre-op RT not needed for all, but here is my take on 5 settings should still consider. Key is patient selection, weighing risks of local vs. distant recurrence. @OncoAlert

#ESMO25 turning 🧊 ➡️🔥? 🚨The phase 3 STELLAR-303 trial evaluated zanzalintinib + atezolizumab vs regorafenib in 901 patients with previously treated, non–MSI-H/dMMR mCRC. 💡 Zanzalintinib is a novel multitargeted TKI that inhibits TAM kinases (TYRO3, AXL, MER), MET, and VEGF

🔥data at #ESMO25 #ESMO2025 this morning from @sara_lonardi1 : ⭐️prelim OS 78% at 5 years with ipi/nivo in CM-8HW -@skopetz : ⭐️Chemo +EC leads to fewer resistance mutations than EC alone and absolutely masterful discussion as usual by @GillSharlene, including clues as to who may

Update of #Checkmate8HW first-line subgroup for PFS with early overall OS results from @sarah_lonardi1 @esmo #ESMO25 #cancer #cancerresearch @bmsnews

IKF-035/ABC-HCC phs IIIb: Atezolizumab + Bevacizumab vs TACE in intermediate-stage HCC #ESMO25 #ESMOAmbassadors 👉 TTFS: 14 vs vs 9 mo 🧐BCLC B is not any more the ”domain” of local therapies, but intent of treatment is more than ever key for MDT discussion @myesmo @EASLedu

Does chemotherapy affect the biology of BRAF V600E mCRC when combined with encorafenib + ceruximab? Answer appears to be YES! Very intriguing translational finding showing that addition of chemo to E+C reduces development of acquired RAS, MAP2K1 , and other mutations that drive

TRIPLET HCC ➡️atezo/bev + 1mg ipi vs atezo/bev ➡️no improvements in ORR /PFS/ OS ➡️higher toxicity despite 1mg ipi Need to mind the liver! #ESMO25 @ILCAnews @bruixj

HRS-4642: KRAS G12D specific inh ➡️30 pts with first-line GnP ➡️ORR 63% ➡️87% >|=grade 3 AEs - most haem ‼️imp for trial design of combos ?sequencing ? Maintenance ➡️ctDNA role emerging ? Adaptive designs #esmo2025 #PDAC @OncoAlert

📢 #ESMO25 | #NETs COMPETE trial: ¹⁷⁷Lu-edotreotide vs everolimus in G1–2 GEP-NETs 🧩 mPFS 23.9 vs 14.1 mo | HR 0.67 (95% CI 0.48–0.95); p=0.022 🧩 ORR 22% vs 4% (p<0.0001) ⚕️ Drug-related discontinuations: 2% vs 15% 💡 ¹⁷⁷Lu-edotreotide outperforms everolimus, safer ✅

Unfortunately another negative triplet #HCC ➡️ IMbrave152/SKYSCRAPER-14 Atezo/bev/ tiragolumab (anti-tigit) v.atezo/bev ➡️mPFS 8.3 vs 8.2; HR OS 0.94 ➡️more toxicity However in this triplet - little activity evident ; need understand tigit role #esmo2025 @OncoAlert @ILCAnews

Comprehensive overview of treatment sequencing in #HCC #ESMO2025👏🏻 ➡️how to choose IO options first-line ➡️TKI choices second-line, limited data and difficulties in accessing treatments ➡️importance of pt factors at MDT ➡️biomarkers still a huge unmet need @DrAngelaLamarca

PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II CRC patients #ESMO25 #ESMOAmbassadors 👉ctDNA trajectories define prognosis 👉 3yr-DFS: 82 (-) vs 58% (+) 🧐Very innovative trail design, ctDNA guided ACT is the future @myesmo

⭐️Intermediate stage HCC⭐️ ➡️how to integrate LRT/IO; do we need for all,what is tace eligible ➡️which LRT-immunogenicity evident ➡️patient factors imp ➡️curing select bclc b with effective tx ➡️endpoint considerations imp in trial design 🎉fabulous overview @DJPinato #esmo2025

The results of the COMPETE trial (LU-177 DOTATOC vs. everolimus is mostly second line therapy (small subset 1st line). Radioligand therapy superior to everolimus. #ESMO25 @Ja_Capdevila

It used to take a decade to see so many changes in practice Now it takes one single conference day. #ESMO25 #ESMOAmbassadors

RC118 (CLDN18.2-ADC) combined with PD-1 blockade or RC148 (PD-1/VEGF bispecific) for locally advanced la/m G/GEJA #ESMO25 #ESMOAmbassadors 👉ORR: 57 vs 33% , DCR: 95 vs 67% 👉mPFS: 7.9 vs 4.3 mo 🧐Interesting efficacy for the bispecific AB in combo with anti-CLDN18.2 @myesmo

📢KC-WISE Upper GI proffered #ESMO25 ➡️Met. HER2+ gastric/GEJ, previosly treated with trastuzumab ➡️Anbenitamab-ChT vs ChT ✅PFS: 7.1 vs. 2.7 months HR: 0.25; (0.17 to 0.39) P<0.0001 😮 ✅OS: 19.6 vs. 11.5 months HR: 0.29; (0.17 to 0.50) P<0.00001 😮 ✅ORR: 56% vs. 11%

Domvanalimab, zimberelimab, and FOLFOX in advanced GC/GEJC/EAC #ESMO25 #ESMOAmbassadors 👉 ORR: 59%, TAP>5% 69% 👉 mPFS: 12.9 mo 👉 mOS: 26.7% 🧐Promising efficacy for anti-TIGIT plus anti-PD1 @myesmo